Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations

The Conference Board of Canada, 69 pages, April 27, 2017
Report by ,
4.0/5 based on 2 reviews
(You must be signed in and entitled to rate this report)
This report examines the savings generated by increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two populations at high risk for cardiovascular disease.

Document Highlights

Cardiovascular disease (CVD) prevalence incurs significant costs to governments and society in the form of hospitalizations, disease management, and lost productivity. Also, some individuals are at increased risk of a first or repeat CVD event due to high LDL cholesterol (LDL-C) levels. This report investigates the impact of increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two high-risk populations.

Discover why PCSK9i, recommended by Canadian guidelines for the treatment of dyslipidemia in high-risk patients, can lead to billions of dollars in direct cost savings to the Canadian health care system and indirect cost savings from lost productivity due to premature mortality and hospitalizations.

Table of Contents

EXECUTIVE SUMMARY

Chapter 1–Introduction

Chapter 2–Methodology

  • Target Populations
  • PCSK9 Inhibitors
  • Population Model
  • Mortality
  • Costs

Chapter 3–Results

  • Heterozygous Familial Hypercholesterolemia
  • Secondary Prevention (SP)

Chapter 4–Conclusion

Appendix A–Detailed Results

Appendix B–Bibliography

Access document

(you will be asked to sign-in)

Price: $0
You can get this research for free. Take a minute and create an e-Library account.